Masimo Co. (NASDAQ:MASI) Director Sells $5,446,800.00 in Stock

Masimo Co. (NASDAQ:MASI) Director Craig B. Reynolds sold 40,000 shares of the stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $136.17, for a total value of $5,446,800.00. Following the transaction, the director now owns 7,406 shares in the company, valued at approximately $1,008,475.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Masimo Stock Performance

NASDAQ MASI opened at $136.25 on Friday. Masimo Co. has a 1 year low of $75.22 and a 1 year high of $189.30. The firm has a market capitalization of $7.21 billion, a price-to-earnings ratio of 90.23 and a beta of 0.99. The company has a current ratio of 2.18, a quick ratio of 1.22 and a debt-to-equity ratio of 0.64. The firm’s 50 day simple moving average is $136.00 and its 200 day simple moving average is $117.83.

Masimo (NASDAQ:MASI) last issued its earnings results on Tuesday, February 27th. The medical equipment provider reported $1.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.82 by $0.43. Masimo had a return on equity of 13.77% and a net margin of 3.98%. The firm had revenue of $548.90 million for the quarter, compared to the consensus estimate of $545.69 million. During the same quarter last year, the business posted $1.32 EPS. The company’s revenue was down 11.0% compared to the same quarter last year. As a group, research analysts expect that Masimo Co. will post 3.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have commented on MASI shares. BTIG Research upped their price objective on Masimo from $145.00 to $166.00 and gave the company a “buy” rating in a report on Monday, March 25th. StockNews.com raised shares of Masimo from a “sell” rating to a “hold” rating in a research report on Friday, March 29th. Jefferies Financial Group restated a “hold” rating and set a $121.00 target price (up previously from $107.00) on shares of Masimo in a research report on Tuesday, January 30th. Piper Sandler lifted their price target on shares of Masimo from $70.00 to $117.00 and gave the company a “neutral” rating in a research report on Monday, February 26th. Finally, Wells Fargo & Company raised Masimo from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $117.00 to $160.00 in a research report on Monday, March 25th. Five investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Masimo currently has an average rating of “Hold” and a consensus price target of $137.43.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in MASI. Massachusetts Financial Services Co. MA acquired a new position in Masimo during the 3rd quarter worth approximately $132,699,000. Eminence Capital LP bought a new position in shares of Masimo in the 3rd quarter valued at $90,859,000. Schroder Investment Management Group boosted its holdings in shares of Masimo by 59.6% during the 4th quarter. Schroder Investment Management Group now owns 877,539 shares of the medical equipment provider’s stock valued at $102,856,000 after acquiring an additional 327,863 shares in the last quarter. Hawk Ridge Capital Management LP grew its position in Masimo by 124.4% during the 3rd quarter. Hawk Ridge Capital Management LP now owns 567,765 shares of the medical equipment provider’s stock worth $49,782,000 after acquiring an additional 314,763 shares during the last quarter. Finally, Westfield Capital Management Co. LP increased its holdings in Masimo by 35.6% in the 4th quarter. Westfield Capital Management Co. LP now owns 818,476 shares of the medical equipment provider’s stock worth $95,934,000 after purchasing an additional 214,795 shares in the last quarter. Institutional investors own 85.96% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.